Head of Business Development for Neuroscience and West Coast BD, GSK
Neil Berkley has been with GSK since 2014 and is the Head of Business Development for Neuroscience and West Coast BD. Neil is also site head of the San Diego R&D satellite office and a member of the transactions team at GSK. Before joining GSK, Neil was Head of Business Development at Cadence Pharmaceuticals, a commercial stage acute care company, where he was part of the team who successfully sold the company to Mallinckrodt for $1.3B in cash. Prior to Cadence, Neil held various roles with a primary focus on business development at Mpex Pharmaceutical, an antibacterial company he co-founded in 2001. During his time at Mpex, Neil helped raise over $100M in venture capital financing and closed multiple business development transactions including an option deal with GSK and the acquisition of Mpex by Aptalis in 2011. Neil also co-founded another San Diego-based biotechnology company, Vaxiion Therapeutics, which is developing a novel therapy for bladder cancer. Prior to his industry experience, Neil worked in several different academic laboratories studying immunology, cardiac virology and microbiology. Neil holds a BS in molecular biology from the University of California, San Diego and an MS in cellular and molecular biology as well as an MBA from San Diego State University.